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Glaucoma associatedwithmetered-dose
bronchodilator therapy
The risk of exacerbating pre-existing or undiagnosed
acute angle-closure glaucoma in patients receiving nebu-
lized therapy with b-adrenergic agents and ipratropium
bromide (IB) for chronic obstructive pulmonary disease
(COPD) is well documented. Although glaucoma has
been reported in associationwith IB alone, case reports
suggest that an additive e¡ect of combined therapy with
nebulized salbutamol and IB is responsible for precipitat-
ing it (1^7). All the reports about this subject are case
reports except for the double-blind cross-over study, in
which the patients who already had glaucoma were
assessed to determine if nebulized salbutamol and IB
therapy had any e¡ect on intraocular pressures (8). To
our knowledge, there is onlyone casereport about glau-
coma associated with metered-dose bronchodilator
therapy (1).
We therefore decided to determine whether
metered-dose IB-salbutamol combination can cause
glaucoma and to compare the results with the use of
formoterol via metered-dose inhaler as a control
group. Twenty stable COPD patients (M/F :15/5, mean
age 57?7+12?0 years) who were admitted to our
outpatient department during a period of 6 months,
were divided into two groups: 10 of them were
treated with IB 20mcg^ salbutamol 100mcg combina-
tion given every 6 hours (group 1) and the others
with formoterol 24mcg bid (group 2).There was no dif-
ference between the two groups regarding the age,
sex, duration and severity of COPD and previous use
of bronchodilators (data shown in part in Table 1). All
the patients were using bronchodilators via a metered-TABLE 1. The demographicdata ofthe study and controlgroup
Group1
Mean age (yrs) 58?1+9?3
Sex (F :M) (n) 1: 9
Duration of COPD (yrs) 13?7+11?4
Severityof COPD* (n)
Mild 5
Moderate 2
Severe 3
*Weused the AmericanThoracic Societycriteria.dose inhaler, not with a nebulizer, except for eight
newly diagnosed COPD cases (three from group 1 and
¢ve from group 2).
We assessed visual acuity, slit-lamp examination, in-
traocular pressure (IOP) and iridocorneal angles at the
initial visit, 1 and 4 weeks later and every 3 months
each year in all patients.Visual ¢elds were also evaluated
in the ¢rst, sixth and twelfth months.
None of the patients had glaucoma at the initial visit
and one of them had a family history of glaucoma. How-
ever, with ophthalmologic examination we observed
bilateral rise in IOP anddefects of thevisual ¢eld in three
patients (30%) in group 1 during the follow-up. Angle
narrowing was detected in two of these three patients.
In group 2, therewerebilateral rise in IOP, angle narrow-
ing and defects of the visual ¢eld in one patient (10%),
whose mother also had glaucoma.There was no signi¢-
cant di¡erence in IOP increase between the two groups.
The incidence of glaucoma has been estimated as1?2%
in patients older than 40 years old (9). However, in this
study we determined that IB-salbutamol administration
even by metered-dose inhaler can cause glaucoma in
three of10 patients (30%). In the control groupwith for-
moterol, glaucomawas also observedin onepatientwith
a predisposing factor, namely family history. These pre-
disposing factors include a family history of glaucoma,
increasing age, female gender, congenitally small anterior
segments as found in microcornea, nanophthalmos and
hyperopia, shallow anterior chamber depth and
increased lens thickness (2).
The raised intraocular pressures seem to be a topical
e¡ect of ipratropium bromide and salbutamol solution
escaping from the facemaskof thenebulizer, rather than
a systemic e¡ects of these drugs (8).The use of bronch-
odilator agents viametered-dose inhalerswas also founds
Group 2 P
57?0+10?9 0?42
4: 6 0?08
13?4+8?6 0?48
0?11
6
3
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to explain this is autoinoculation by a ¢nger contami-
nated with the drug or systemic absorption via the
respiratory tract (2).We conclude that when metered-
dose bronchodilators, especially anti-cholinergic agents,
are prescribed to the COPD patients who have risk
factors for glaucoma, ophthalmologic examinations
should be done periodically. But further studies are
needed to determine whether they have an e¡ect on
intraocular pressures or not.
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